Trial reportThe Annals of thoracic surgery2018
Induction Cisplatin Docetaxel Followed by Surgery and Erlotinib in Non-Small Cell Lung Cancer.
Trial report in The Annals of thoracic surgery, 2018. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 21 papers, 2 of them syntheses that pooled it.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
21 citing papers in PubMed, 2 syntheses or guidelines pooled it.
- Neoadjuvant Chemoimmunotherapy for NSCLC: A Systematic Review and Meta-Analysis.JAMA oncology · 2024Pooled it
- Pathological response in resectable non-small cell lung cancer: a systematic literature review and meta-analysis.JNCI cancer spectrum · 2024Pooled it
- Neoadjuvant osimertinib with/without chemotherapy versus chemotherapy alone forFuture oncology (London, England) · 2021Trial
- Neoadjuvant nivolumab or nivolumab plus ipilimumab in operable non-small cell lung cancer: the phase 2 randomized NEOSTAR trial.Nature medicine · 2021Trial
- Acute severe hypokalemia caused by treatment of tongue squamous cell carcinoma with docetaxel and cisplatin: A case report.World journal of clinical oncology · 2024Article
- [Progress on Neoadjuvant Immunotherapy for Resectable Non-small Cell Lung Cancer].Zhongguo fei ai za zhi = Chinese journal of lung cancer · 2024Review
- Pathologic Processing of Lung Cancer Resection Specimens After Neoadjuvant Therapy.Modern pathology : an official journal of the United States and Canadian Academy of Pathology, Inc · 2024Article
- International expert consensus on immunotherapy for early-stage non-small cell lung cancer.Translational lung cancer research · 2022Review
- Immune-based therapies in penile cancer.Nature reviews. Urology · 2022Review
- Neoadjuvant immunotherapy across cancers: meeting report from the Immunotherapy Bridge-December 1st-2nd, 2021.Journal of translational medicine · 2022Article
- Neoadjuvant PD-1 inhibitor combines with chemotherapy versus neoadjuvant chemotherapy in resectable squamous cell carcinoma of the lung.Thoracic cancer · 2022Article
- Neoadjuvant immunotherapy and neoadjuvant chemotherapy in resectable non-small cell lung cancer: A systematic review and single-arm meta-analysis.Frontiers in oncology · 2022Article
- Real-world multicentre analysis of neoadjuvant immunotherapy and chemotherapy in localized or oligometastatic non-small cell lung cancer (KOMPASSneoOP).Therapeutic advances in medical oncology · 2022Article
- Neoadjuvant Therapy in Lung Cancer: What Is Most Important: Objective Response Rate or Major Pathological Response?Current oncology (Toronto, Ont.) · 2021Review
- Evolution of systemic therapy for stages I-III non-metastatic non-small-cell lung cancer.Nature reviews. Clinical oncology · 2021Review
- New developments in locally advanced nonsmall cell lung cancer.European respiratory review : an official journal of the European Respiratory Society · 2021Article
- Emerging biomarkers for neoadjuvant immune checkpoint inhibitors in operable non-small cell lung cancer.Translational lung cancer research · 2021Review
- A Phase I/II Study of Neoadjuvant Cisplatin, Docetaxel, and Nintedanib for Resectable Non-Small Cell Lung Cancer.Clinical cancer research : an official journal of the American Association for Cancer Research · 2020Article
- IASLC Multidisciplinary Recommendations for Pathologic Assessment of Lung Cancer Resection Specimens After Neoadjuvant Therapy.Journal of thoracic oncology : official publication of the International Association for the Study of Lung Cancer · 2020Review
- Induction systemic therapy followed by surgery for stages II-III non-small cell lung cancer: steady efforts.Journal of thoracic disease · 2018Article
Corrections and comments
- Commented on by
- Commented on by
Authors and funding
15 authors.
Funding
Abstract
backgroundData from meta-analyses support the use of induction or adjuvant platinum-based chemotherapy for locally advanced non-small cell lung cancers (NSCLCs). This phase 2 study assessed the role of induction cisplatin and docetaxel followed by surgery in patients with resectable stage I to III NSCLCs, followed by 12 months of adjuvant erlotinib.
methodsPatients with resectable stage I to III NSCLCs received cisplatin 80 mg/m
resultsForty-seven eligible patients received a median of 3 cycles of induction treatment, 37 underwent surgical resection, and only 21 received adjuvant erlotinib. Two patients died in the perioperative period (1 sepsis during chemotherapy, 1 acute respiratory distress syndrome postoperatively). Most common grade 3 to 5 toxicities during chemotherapy included hypokalemia (8%), infection (7%), and granulocytopenia (25%). During adjuvant erlotinib, 14% of patients experienced grade 2 rash. Median overall survival was 3.4 years. Major pathologic responses in the primary tumor were observed in 19% (7 of 37) of patients and correlated with improved long-term overall survival. Complete pathologic response in mediastinal/hilar nodes also correlated with superior survival.
conclusionsInduction cisplatin and docetaxel was well tolerated. Adjuvant erlotinib did not improve outcomes compared with historical controls. Major pathologic response predicted for improved long-term survival and is a suitable intermediary endpoint for future phase 2 studies.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.